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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not aspirin 
is effective in helping to prevent breast cancer in women ages 45 years and older. 
 
STUDY DESIGN: Review of three English language primary studies published in 2005, 2007, 
and 2008  
 
DATA SOURCES: Two randomized, double blind, placebo controlled clinical trials and one 
prospective, population based cohort study comparing aspirin to placebo were found using 
PubMed and Cochrane databases.  
 
OUTCOMES MEASURED: Breast cancer development was measured in several ways. Tumor 
characteristics were measured at diagnosis, including size, metastasis to lymph nodes, histology 
of the mass, histology differentiation, and estrogen and progesterone status. Outcomes were also 
measured by pathology reports, cytology reports, on strong clinical and radiologic or laboratory 
marker evidence, and also self reported questionnaire.  
 
RESULTS: The two randomized controlled trials showed that the use of aspirin has no 
significant effect on the prevention of breast cancer. The cohort study showed an inverse 
relationship between the use of aspirin and the risk of cancer incidence and mortality. 
 
CONCLUSIONS: Although the two RCTs showed no effect of aspirin on the prevention of 
breast cancer, the cohort study showed some promise in the use of aspirin and breast cancer 
prevention. The dose of aspirin used in the RCTs was only 100mg, and the doses in the cohort 
study varied based on individual reporting. Increasing the dose of aspirin to 325mg in future 
studies may show some effect in the prevention of breast cancer.  
 
KEY WORDS: Aspirin, Breast Cancer  
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INTRODUCTION 
 Breast cancer is defined as “a malignant proliferation of epithelial cells lining the ducts or 
lobules of the breast”, resulting from a single cell that undergoes acquired or germ-line mutations, 
and eventually expresses “full malignant potential”.1 After skin cancer, breast cancer is the most 
commonly diagnosed cancer in U.S. women, with death rates higher than for any other cancer, 
besides lung cancer. Mortality has decreased slightly due to early detection methods; however 
prevention of the disorder could further lower mortality. One in eight women in the United States 
will develop breast cancer during her lifetime. About 85% of breast cancer cases occur in women 
with no prior family history of breast cancer. In 2011, “230,480 new cases of invasive breast 
cancer were expected to be diagnosed in women in the U.S.”, with “57,650 new cases of non-
invasive (in situ) breast cancer”, and “39,520 women in the U.S. were expected to die in 2011 
from breast cancer”.2 The national expenditure for breast cancer care in 2006 was $13.886 
billion.3 
 The biggest risk factor for the “development of breast cancer is age”, with the median age 
of diagnosis of 61 years, though many women with breast cancer do not have any “identifiable 
risk factors”. 4 The initial discovery of breast cancer in about 70% of patients is a lump in the 
breast that is “single, non-tender” and “firm to hard with ill-defined margins”4. Mammography is 
useful in that it detects masses before they can be palpated, sometimes even 2 years prior to 
being felt in the case of slow growing cancers. The most common method of treating breast 
cancer is surgical resection which can be breast conserving or a full mastectomy. Other treatment 
methods include chemotherapy, radiation therapy and hormone therapy such as ERDs, SERMs 
and aromatase inhibitors.4 
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 Evidence has shown that aspirin might be effective in the prevention of breast cancer, so 
that women will not have to undergo such invasive measures to treat breast cancer in the future. 
NSAIDS have been shown to “suppress tumor growth” in “experimental animal models”5. 
Observational epidemiological studies have suggested a strong inverse association, with risk 
reduction 20-50% for various sites in several different cancer types, including breast cancer. 
Aspirin is thought to reduce cancer risk through its effect on cyclooxygenase (COX). Aspirin 
inhibits COX enzymes, particularly COX 2 which is “linked to inflammation and tumor growth”, 
effecting “apoptosis, cell migration and angiogenesis”5. There is also a possible role of aspirin as 
an antioxidant and in the “modulation of estrogen biosynthesis”.5  
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not aspirin is 
effective in helping to prevent breast cancer in women ages 45 years and older.  
METHODS 
 The criteria for selection of studies included women ages 45 years and older. The 
intervention used was aspirin use. The types of studies included consist of two randomized 
control trials (RCT) and a prospective, population based cohort study. In each RCT, results are 
compared between the groups taking aspirin and the placebo group. The cohort study compares 
groups taking aspirin to those not taking medication6. The outcomes measured are breast cancer 
incidence and mortality.  
 Articles were found via Pubmed and Cochrane. The key words used in searches were 
“aspirin” and “breast cancer”. All articles are written in English and were published in peer 
reviewed journals. Articles were selected based on their relevance and on the importance of 
outcomes of the patient or POEMs. Inclusion criteria consisted of articles using aspirin as an 
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intervention, female participants aged 45 years and older, and studies that were randomized 
controlled trials. Exclusion included any observational studies prior to 2005 because of an 
already existing non-Cochrane meta-analysis. The statistics reported of use include  
Relative Risk (RR), 95% Confidence Interval (CI), Relative Risk Reduction (RRR), Absolute 
Risk Reduction (ARR), Numbers Need to Treat (NNT), and p-value. Table 1 includes the 
demographics of the included studies. 
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Table 1: Table of Demographics and Characteristics of included studies 
Study Type # Pts Age 
(yrs) 
Inclusion 
criteria 
Exclusion 
criteria 
W/D Intervention
s 
Bardia, 
20076  
 
Prospective, 
population 
based 
cohort study 
22507 55-
69 
Postmenopausal 
women 
Premenopausal, 
cancer other than 
nonmelanoma 
cancer, receiving 
chemotherapy 
through 1992, 
history of heart 
disease through 
1992, died 
between 1986 
and 1992, did 
not complete 
1992 
questionnaire 
0 Self 
reported 
aspirin or 
NSAID 
intake 
Cook, 
20055 
 
RCT 39,876 45 
years 
and 
older 
No history of 
cancer or 
cardiovascular 
disease or other 
major chronic 
illness 
History of 
adverse effects 
to aspirin; taking 
aspirin or 
NSAIDs more 
than once a 
week; taking 
anticoagulants or 
corticosteroids; 
taking vitamin 
A, vitamin E or 
beta carotene 
more than once a 
week 
0 Low dose 
aspirin, 100 
mg 
administere
d every 
other day 
for 10 years 
Zhang, 
20087 
 
Double 
blind, RCT 
39,876 45 
years 
and 
older 
No history of 
cancer or 
cardiovascular 
disease or other 
major chronic 
illness 
History of 
adverse effects 
to aspirin; taking 
aspirin or 
NSAIDs more 
than once a 
week; taking 
anticoagulants or 
corticosteroids; 
taking vitamin 
A, vitamin E or 
beta carotene 
more than once a 
week 
0 Low dose 
aspirin, 100 
mg 
administere
d every 
other day 
for 10 years  
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OUTCOMES MEASURED 
 All outcomes measured were based on relevance to Patient Oriented Evidence that 
Matters (POEMS). Zhang et. al. measured outcomes based on “tumor characteristics at 
diagnosis”, including size, metastasis to lymph nodes, histology of the mass, histologic 
differentiation, estrogen and progesterone receptor status7. Cook et. al. measured outcomes based 
on pathology reports, cytology reports and on “strong clinical and radiological or laboratory 
marker evidence”5. For reported cases of breast cancer, medical records and other relevant 
information was sought and reviewed by physicians blinded to the treatment5. Lastly Bardia et. al. 
measured outcomes based on self reported questionnaire, with cancer incidence and mortality 
ascertained by annual linkage to the “Iowa Surveillance, Epidemiology and End Results Cancer 
Registry and death certificates”6.  
RESULTS 
 Bardia et. al. determined the effects of aspirin on breast cancer through a prospective, 
population based cohort study, in which participants were analyzed via their returned 
questionnaires. The study found that during 10 years of follow up, “3487 cases of cancer were 
observed”, with an “inverse trend for cancer risk with frequency of aspirin use (Ptrend<0.001)” 
observed6. The use of aspirin was inversely associated with cancer incidence, as seen in table 2. 
Table 2: Relative Risk and 95% Confidence Interval for Incidence of Breast Cancer in 
Those Taking Aspirin 
Bardia et. al. 2007 
Aspirin Use per week RR 95% CI 
Never 1.00 Referent 
Ever 0.84 0.80 to 0.93 
≤1 0.85 0.70 to 0.93 
2-5 0.83 0.77 to 0.94 
≥6 0.81 0.80 to 0.98 
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 Bardia et. al. found a “weak inverse association between the frequency of aspirin use and 
cancer mortality”, with aspirin ever use “inversely associated with cancer mortality (RR = 0.87, 
95% CI = 0.76 to 0.99)”, as seen in table 3.6   
Table 3: 95% Confidence Interval for Incidence and Mortality of Breast Cancer in Those 
Taking Aspirin 
Bardia et. al. 2007 
Aspirin Use per week RR 95% CI 
Never 1.00 Referent 
Ever 0.87 0.76 to 0.99 
≤1 0.91 0.78 to 1.06 
2-5 0.83 0.69 to 1.00 
≥6 0.82 0.68 to 0.99 
 
Bardia et. al. excluded women who were premenopausal, had cancer or who were 
receiving chemotherapy since these groups would alter the incidence of breast cancer and would 
make it difficult to determine if aspirin had an effect. The study observed differences in smokers 
versus nonsmokers. The “inverse association between aspirin use and breast cancer mortality 
was evident among never smokers (for aspirin use six or more times per week versus never use, 
95% CI = 0.61 to 0.99) and suggestive among former smokers (for aspirin use six or more times 
per week versus never use, 95% CI = 0.51 to 1.24) but not among current smokers (for aspirin 
use six or more times per week versus never use, 95% CI = 0.63 to 1.46)”6.  The study also 
looked at the effect of NSAIDs and the risk of cardiovascular incidences with both aspirin and 
NSAIDs.  
Zhang et. al. looked at cases of total, invasive and in situ breast cancer, finding no 
significant effect on risk with low dose aspirin according to tumor size, histology and estrogen or 
progesterone receptor status. Total cases of breast cancer with aspirin treatment was “762 cases”, 
while the total cases with placebo treatment was “779 cases”, with a “95% CI of 0.88 – 1.08”7. 
Cases of in situ breast cancer with aspirin treatment was “159 cases”, while the cases of in situ 
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cancer with placebo treatment was “165 cases”, with a “95% CI of 0.78 to 1.20”7. Cases of 
invasive breast cancer with aspirin treatment was “608 cases”, while the cases of invasive cancer 
with placebo treatment was “622 cases”, with a “95% CI of 0.87 to 1.09” as seen in table 47. 
“Morbidity and mortality follow-up were 97.2% and 99.4%” respectively (deaths were reported 
by “family members, postal authorities, and a search of the National Death Index”) 7. The 
number needed to treat (NNT) was -1429, meaning that for every 1429 participants who took 
prophylactic aspirin, there was one fewer incidence of breast cancer than in the group of 
participants taking placebo.  
Table 4: Cases of Breast Cancer According to Randomized Aspirin Treatment 
Zhang et. al. 2008 
 Number of cases with 
Aspirin (n=19934) 
Number of cases with 
placebo (n=19942) 
Hazards 
Ratio 
95% CI 
Total Breast 
Cancer 
762 779 0.98 0.88 – 
1.08 
In situ Breast 
cancer 
159 165 0.96 0.78 - 
1.20 
Invasive Breast 
cancer 
608 622 0.98 0.87- 
1.09 
 
 Cook et. al. found after 10 years of follow up, there were “1230” cases of invasive breast 
cancer, with “1535” cases of in situ breast cancer5. There was no effect of aspirin on the 
incidence of breast cancer with the “95% CI of 0.87 to 1.09 and p= 0.68”5. Table 5 shows that 
there is no increase in the effect of aspirin over duration of time.  
Table 5: Cumulative Effect of Aspirin on Breast Cancer Prevention over Time  
Cook et. al. 2005 
Follow up time 95% CI P 
2 years 0.87 – 1.09 0.74 
5 years 0.83 – 1.12 0.63 
 
Cook et. al. also compared the incidence of breast cancer in smokers and nonsmokers. 
“Among never smokers, women assigned to aspirin had an increased risk (95% CI = 0.94 – 1.30, 
Quartuccio, Aspirin and Breast Cancer   8 
p=0.21), but among past smokers they had a decreased risk (95% CI = 0.94 – 1.30, p=0.07), with 
no effect among current smokers (95% CI = 0.69-1.25, p= 0.63)”5. The study took into account 
compliance of participants as well. There were no effects on breast cancer in women at the time 
they stopped taking “at least two thirds of their study pills”5. “Among women who consistently 
took at least two thirds of their study aspirin or placebo during the first 2 years”, there was no 
effect on breast cancers occurring after 2 years of follow up “(95% CI = 0.87 – 1.13 and p = 
0.88)”, and “the same was true among women who complied with study medication use during 
the first 5 years of intervention”5. The study also looked into the effect of aspirin on several other 
types of cancers. The NNT in this RCT was -1429. 
DISCUSSION 
 The two RCTs used aspirin at dosages of 100 mg every other day while the prospective 
cohort study asked participants to report only how regularly they took aspirin and not the amount. 
Taking higher doses of aspirin more regularly might provide some benefits.  
 Aspirin is widely available and convenient for patients in that it is over the counter. 
Contraindications to use include hypersensitivity to salicylates or other NSAIDs, asthma, rhinitis, 
nasal polyps, inherited or acquired bleeding disorders or pregnancy. Adverse effects include 
salicylate sensitivity, tinnitus, and upper gastrointestinal events.8 
 Limitations existed in the articles included in this paper. In all of the studies, patients 
were responsible for taking medication and reporting how compliant they were. The studies were 
not performed in in-patient settings where they could be monitored because they persisted for a 
decade. There is some variability in the results in that some patients might not have been 
accurate in recording how much medication they took. The cohort study was not performed as a 
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double blind RCT, but instead participants filled out questionnaires about the medications they 
took and how often.  
 There were limitations in searching for articles as well. There are an abundance of cohort 
studies but few RCTs on the topic at hand. RCTs are more useful in that that they typically 
perform studies in a double blind fashion, which eliminates bias.  
CONCLUSION 
 According to the two RCTs, aspirin is not effective in preventing breast cancer in women 
ages 45 years and older. The prospective cohort study however did show aspirin to be effective 
in preventing breast cancer in women ages 45 years and older. The issue at hand comes down to 
dosage. Participants who received aspirin in the RCTs took 100mg every other day of aspirin. In 
the cohort study, participants recorded how often they took aspirin, which could have ranged in 
value with some even taking 325mg (the study does not state the amounts). Cook et. al. states 
that low dose aspirin appears “relatively specific for COX-1”, though “higher doses inhibit both 
COX-1 and COX-2 and may have a stronger anti-inflammatory effect”5. “COX-2 expression” is 
“increased in breast cancer tumor tissue”, which suggests that “higher doses of aspirin may be 
more effective in cancer prevention”5.  
 Future study is warranted to determine if higher dosages of aspirin at closer intervals is 
more effective than 100 mg of aspirin every other day7.  The most effective way to determine 
this is by a double blind RCT comparing the higher and lower dosages of aspirin against a 
placebo.  
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